1. Introduction {#sec1}
===============

Coronary heart disease (CHD) is the leading cause of death in most countries, with a high prevalence currently driven by dual epidemics of obesity and diabetes \[[@B1]\]. Statins are the hypolipidemic treatment of choice for hyperlipidemia with a confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients \[[@B2]\]. Statin drugs are the most effective, evidence-based agents to prevent and treat this disease. Statins have a central role in management and are advised in all published guidelines \[[@B1]\]. Currently, dyslipidemia treatment is based on individualized risk factor assessment. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhAHDCDT_3987065/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol \[[@B3]\] recommends the use of statins based on risk factors for cardiovascular disease, rather than low-density lipoprotein (LDL) level targets that were formerly used to guide statin intensity according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) dyslipidemia guideline \[[@B4]\].

Nowadays, with the emergence of new preparations and therapeutics, as well as the appearance of some adverse reactions and tolerance phenomenon of statins in their applications, the statin monotherapies have been questioned \[[@B1], [@B2], [@B5]\]. Nonstatin therapy has gradually entered the field of vision \[[@B6]\]. However, in the clinical practice, evidence such as RCTs, guidelines, and recommendations for these nonstatin therapies are very limited, which provides little evidence-based efficacy support for clinicians to use only nonstatin therapies in the treatment of dyslipidemia. Therefore, at present, statins are still one of the main drugs for the treatment of hyperlipidemia, especially in combination with other drugs. Absolute nonstatin therapies should only be considered in high-risk patients who have a suboptimal response to statins and/or are intolerant to statin therapy \[[@B6]\].

When it comes to choosing one statin treatment among multiple alternatives, scientific evidence is particularly important. However, existing evidence is insufficient to inform prescribing decisions. While traditional meta-analyses synthesize existing RCT data and compare the efficacy between two statin treatments, network meta-analysis allows for the combination of direct and indirect evidences from randomized trials, facilitating the comparison of all kinds of statins even when they are not directly compared with each other in clinical trials \[[@B7]\].

To date, some statin-related studies have focused on the comparison between statin combination therapies with statin monotherapies \[[@B8], [@B9]\], and others (mainly network meta-analyses) have focused on the comparative tolerability or comparative effects among different statins \[[@B10], [@B11]\]; however, the outcome indicators were mainly the occurrence and outcome of relevant diseases. In 2014, Naci et al. published a network meta-analysis using the absolute value of lipid as the primary efficacy indicator of different statins \[[@B12]\]. Similar to the method used in this article, the change values of lipids were chosen as the primary endpoint of our network meta-analyses. The direct lipid-lowering/increasing effects of the 7 statins were compared in this study, providing a reference and evidence-based foundation for drug selection in both statin monotherapies and statin combination therapies.

2. Materials and Methods {#sec2}
========================

This paper conforms with the PRISMA-NMA guidance \[[@B13]\]. The trial was registered with PROSPERO (number [CRD42018108799](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018108799)) \[[@B14]\].

2.1. Data Sources and Searches {#sec2.1}
------------------------------

A systematic literature review of Cochrane Library, EMBASE, PubMed, and Web of Science electronic databases was performed to identify RCTs comparing the lipid-lowering/increasing effect of no less than two types of the included statins or the effect of placebo and no less than one type of the included statin. Articles published through February 25, 2020, were searched using the following keyword combination strategy: lovastatin (All Fields) OR pravastatin (All Fields) OR simvastatin (All Fields) OR fluvastatin (All Fields) OR atorvastatin (All Fields) OR rosuvastatin (All Fields) OR pitavastatin (All Fields) OR statins (All Fields) AND randomized controlled trial (All Fields). A complete detailed search strategy is included in Appendix S1. EndNote software version X8 was used throughout the literature search and screening process.

2.2. Study Selection {#sec2.2}
--------------------

The literature search was independently conducted by three authors (XZ, LX, and XJ); in cases of disagreement, a consensus was reached through group discussion. A study was eligible for inclusion if the following criteria were met: (a) a RCT where the random methods, control groups, and blind methods were all included; (b) the study comparing the lipid-lowering efficacy of more than two included statins or placebo with one of the included statins; (c) therapeutic doses of the statins which were administered in the study; and (d) the absolute value change of one of the following six indicators after drug administration which could be directly extracted or calculated from the outcomes of the study: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), Human Apolipoprotein A-1 (ApoA1), and Human Apolipoprotein B (ApoB).

Potentially relevant papers and abstracts were obtained, and the full-text editions were reviewed for inclusion. Studies conducted in healthy volunteers or in patients with diseases other than dyslipidemia, cardiovascular diseases, or diabetes mellitus were excluded. Studies published in languages other than English were excluded.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

An electronic data abstraction form was used to record basic data, including the first author\'s name, publication year, number of subjects, ethnicity, subject status (disease type), drug usage/follow-up duration, and outcomes.

The Cochrane Risk of Bias tool was used to assess the methodological quality of the eligible trails \[[@B15]\]. We scored the chosen articles while extracting data, and RevMan 5.3 was used to generate the literature quality assessment table. Any incongruence between the 3 investigators (XZ, LX, and XJ) was reassessed and discussed until a consensus was reached.

Outcome data, the absolute mean changes, standard deviation (SD) of the lipids after treatment, and *n* (number of patients in a certain group), were mostly calculated according to the baseline and endpoint lipid data in the articles. The mean change values were calculated by subtracting the mean of the endpoints from the mean of the baseline. The calculation method of SD was adopted from Cochrane Handbook version 5.1.0 \[[@B16]\]. The included outcomes were absolute change values of LDL-C, HDL-C, TC, TG, ApoA1, and ApoB. Original data were collected in the form of "mean, SD, and *n*," except for five studies \[[@B17]--[@B21]\], in which the original data for TG were presented in the form of "median, quartiles, and *n*." For these, the mean and SD were estimated using the calculation method described in Wan et al.\'s article \[[@B22]\].

In addition, the units of the outcome indicators were unified by unit conversion for the four outcomes (LDL-C, HDL-C, TC, and TG), while ApoB and ApoA1 did not use unit conversion. In this study, we uniformly used mg·dl^−1^ as the unit of measurement. When the unit provided in the original text was mmol·l^−1^, we multiplied the original data by a certain conversion coefficient and converted it to mg·dl^−1^ as the unit. The methods for unit conversion are shown in AppendixS2.

In our overall NMAs, a method of mixing different dosage groups was adopted. The overall NMAs were conducted only separated by different statin treatments, not by different dosage groups, because 10 of the included studies did not use a fixed drug administration dose, preventing their data from being grouped by different drug dosages. When there were two or more dosage groups for the same statin treatment in one study, we first separately calculated the mean change values, SDs, and *n* (sample sizes) of the patients in different dosage groups according to the method described above, and then we merged these dosage groups using the method introduced in the Cochrane Handbook version 5.1.0 \[[@B23]\]. Six of the included studies used this method to merge two dosage groups of the same statin treatment \[[@B19], [@B24]--[@B28]\]. As a result, in each study, different dosage groups of the same statin (if there were no less than two dosage groups) were eventually processed into a single experimental group for final network meta-analysis.

Since our NMA included patients of different types of diseases (dyslipidemia, cardiovascular diseases, or diabetes mellitus), after conducting the overall NMA, we also conducted subgroup analyses according to different baseline diseases of the patients.

At last, sensitivity analyses were conducted according to age and follow-up duration.

2.4. Data Synthesis and Analysis {#sec2.4}
--------------------------------

We constructed the network meta-analyses by combining direct and indirect evidence. Frequentist NMA was conducted using the network suite and other network-related commands in STATA 15.0 \[[@B29]--[@B31]\]. STATA was also used in the drawing of Network Plots of Network Meta. Global and local inconsistency tests were conducted. Global Wald tests for inconsistency were performed \[[@B32], [@B33]\]. Local inconsistency was explored by a node-splitting method \[[@B33], [@B34]\]. Visual inspection of the funnel plots was conducted separately for the 6 outcomes and used to assess publication bias. In addition, to rank the lipid-lowering/increasing effects of treatments, the surface under the cumulative ranking (SUCRA) was used to summarize the probability values. The SUCRA value was 100% for optimal treatment and 0% for worst treatment \[[@B32]\]. League tables were produced for the 6 outcomes, showing the mixed evidence reported results of pair-wise comparisons among different treatments \[[@B35]\].

Subgroup analyses were conducted according to different baseline diseases. Sensitivity analyses were conducted according to age and follow-up duration.

All data were processed through Review Manager (version 5.3), STATA software (version 15.0), or Microsoft Excel 2016.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

The study selection process is presented in [Figure 1](#fig1){ref-type="fig"}. The bibliographic search retrieved 35814 citations, and after removing duplicates, we reviewed the remaining 27581 articles in the form of a title and an abstract; 650 citations remained after the title and abstract screening. Eventually, after full-text screening, there were 50 studies eligible for the NMA \[[@B17]--[@B21], [@B24]--[@B28], [@B36]--[@B75]\], including 51956 participants. The general characteristics of the included studies are summarized in [Table 1](#tab1){ref-type="table"}. The baseline values of the biochemical parameters in all the included studies are shown in [Table 2](#tab2){ref-type="table"}.

Reflecting methodological quality of the included studies, the Cochrane Risk of bias tool was used, the risk of bias graph is shown in [Figure 2](#fig2){ref-type="fig"}, and the risk of bias summary is shown in [Figure 3](#fig3){ref-type="fig"}. As we can see from [Table 1](#tab1){ref-type="table"}, all of the included patients had dyslipidemia, cardiovascular diseases, or diabetes mellitus. Treatment groups covered all of the seven statin treatments and placebo, and the study populations varied from Americans, British people, Italians, Brazilians, Greek, German to Chinese, Japanese, Koreans etc. The included population groups were diversified. As we can see from [Table 2](#tab2){ref-type="table"}, the baseline values of LDL-C, HDL-C, TC, TG, ApoA1, and ApoB are very close, basically distributed at the same level, and they can be combined for analysis in an integrated NMA.

3.2. Results of the Overall Network Meta-Analyses {#sec3.2}
-------------------------------------------------

50, 45, 43, 40, 15, and 15 studies were separately included in the NMA of the following outcomes: LDL-C, HDL-C, TC, TG, ApoA1, and ApoB. The Network plots are shown in Figures [4(a)](#fig4){ref-type="fig"} -- [4(f)](#fig4){ref-type="fig"}. The nodes represent the individual drugs; lines represent direct comparisons using clinical trials; the thickness of lines represents the number of available clinical trials.

The results of global inconsistency tests are shown in [Table 3](#tab3){ref-type="table"}, where the P values are listed for each outcome. If the *P* value is larger than 0.05, then the inconsistency model is not significant and the data can be analyzed using a consistency model. As is shown in the table, the *P* values are larger than 0.05, except the *P* value in TG NMA, indicating that there is inconsistency between direct and indirect evidences in the NMA for the TG mean change value.

In addition, local inconsistency was tested using a node-splitting method. The node-splitting models revealed statistically significant inconsistency between direct and indirect evidences in the following comparisons in [Table 4](#tab4){ref-type="table"}.

Funnel plots were performed to examine publication bias. No obvious publication bias was observed for the 50 studies. The funnel plots are shown in [Figure 5](#fig5){ref-type="fig"}.

To rank the serum LDL-C-, TC-, TG-, and ApoB-lowering effects of the statins, the surface under the cumulative ranking (SUCRA) was used to summarize the probability values. The HDL-C- and ApoA1-increasing efficacies of the statins were also ranked using this method. The SUCRA value was 100% for the optimal treatment and 0% for the worst treatment. Superposed SUCRA plots are shown in [Figure 6](#fig6){ref-type="fig"}, and the SUCRA values for each treatment in 6 different outcomes are shown in [Table 5](#tab5){ref-type="table"}. Combining the results in the plots and in the table, we can conclude that the comparative treatment efficacy for LDL-C lowering is ROS\>ATO\>PIT\>SIM\>PRA\>FLU\>LOV\>PLA; the comparative efficacy in HDL-C increasing was FLU\>LOV\>PRA\>PIT\>ATO\>SIM\>ROS\>PLA; the comparative TC lowering efficacy was LOV\>ATO\>ROS\>SIM\>PIT\>FLU\>PRA\>PLA; the comparative TG lowering efficacy was LOV\>PRA\>ROS\>FLU\>ATO\>PIT\>SIM\>PLA; their efficacy on ApoA1 increasing exhibited ROS\>SIM\>FLU\>ATO\>LOV\>PLA\>PIT\>PRA; and their efficacy on ApoB-lowering exhibited ROS\>SIM\>ATO\>PIT\>PRA\>FLU\>LOV\>PLA.

The league tables for the 6 NMAs were also produced, the league table for LDL-C NMA is shown in [Table 6](#tab6){ref-type="table"}, and the league tables for the other 5 outcomes can be found in AppendixS3. Estimates are presented by the mean difference with 95% confidence interval (CI) in parentheses. For the NMAs of LDL-C, TC, TG, and ApoB, mean differences below 0 suggest that the treatment listed in the upper row is superior, and mean differences above 0 suggest that the treatment listed in the left column is superior. For the NMAs of HDL-C and ApoA1, mean differences above 0 suggest that the treatment listed in the upper row is superior, and mean differences below 0 suggest that the treatment listed in the left column is superior.

3.3. Results of the Subgroup NMAs {#sec3.3}
---------------------------------

The global and local inconsistency tests of the overall NMAs exhibited inconsistency in several comparisons for the 6 outcomes. The subgroup NMAs were conducted to find out if the inconsistency was originated from the different diseases of the patient groups.

Patients included in the overall NMAs were grouped according to their baseline disease. We divided the patients into three groups: patients with cardiovascular diseases other than simple dyslipidemia (Group 1), dyslipidemia (Group 2), and diabetes mellitus (Group 3). In the subgroup NMAs for LDL-C, each group included 19, 22, and 9 studies, respectively. Frequentist NMAs were separately conducted for the 3 groups for the 6 outcomes. The global and local inconsistency test results are shown in Tables [7](#tab7){ref-type="table"} and [8](#tab8){ref-type="table"}.

As is shown in the tables, the original global inconsistency revealed in the overall NMA for TG was not eliminated by conducting subgroup analyses. Furthermore, for outcomes ApoA1 and ApoB, there were too few articles included in the subgroup NMAs in which data contain no potential source of heterogeneity, and the global and local inconsistency tests could not be conducted.

3.4. Results of the Sensitivity Analyses {#sec3.4}
----------------------------------------

Sensitivity analyses were conducted according to age, follow-up duration, and drug dosage. These analyses were conducted to see if the differences in patients\' age, studies\' follow-up duration, or studies\' drug dosage have contributed to the inconsistency in the overall NMAs. Of the six lipid outcomes, only the overall analysis of the TG-lowering effect revealed inconsistency between direct and indirect evidences. Therefore, we have conducted sensitivity analyses only for this outcome.

The method for age sensitivity analysis was to exclude studies on patients under the age of 18 and conduct NMA for the TG mean change value with the remaining studies. Two studies were excluded because the patients were children or adolescents, and the other 8 studies were also excluded because the age range of the included subjects was unknown. The *P* value of the global inconsistency test after study removal was 0.0000, which still indicates inconsistency between direct and indirect evidences.

The method for follow-up duration sensitivity analysis was to divide the studies into 4 groups: (1) studies with follow-up durations of less than 3 months (including 3 months), (2) studies with follow-up durations of 3months to 1 year (including 1 year), (3) studies with follow-up durations of 1-2 years (including 2 years), and (4) studies with follow-up durations of more than 2 years. The global inconsistency tests were conducted separately for these grouped NMAs for TG outcome. The results are shown in [Table 9](#tab9){ref-type="table"}. As is shown in the table, Group 1 included 13 studies and still revealed inconsistency between direct and indirect evidences, while Group 2 included 7 studies and showed no inconsistency. The difference in follow-up durations might have contributed to the inconsistency in the overall NMAs to some extent.

4. Discussion {#sec4}
=============

In this study, we conducted 6 network meta-analyses for different outcomes in lipid change. The lipid change value was used as the comparison outcome indicator for each of the NMAs. According to the SUCRA results and league tables, ranks of the 7 statins in terms of LDL-C lowering, HDL-C increasing, TC lowering, TG lowering, TC lowering, ApoA1 increasing, and ApoB lowering were concluded, respectively. Generally speaking, rosuvastatin and atorvastatin exhibited rather great efficacy in regulating serum lipids; this has especially confirmed the abundant use of atorvastatin in clinical applications \[[@B4]\].

Based on previous literature, rosuvastatin and atorvastatin are traditionally high-potency statins, which might have the potential in leading to better clinical outcomes than low-potency statins such as pravastatin, simvastatin, fluvastatin, and lovastatin \[[@B76]\]. Three generations of statins have been introduced before \[[@B77]\]: the first generation statins, lovastatin, pravastatin, and fluvastatin, were introduced in the USA in the late 1980s and 1990s; they represent the class members with the lowest potency; the second generation statins, atorvastatin and simvastatin, have significantly improved efficacy in reducing LDL-C levels compared to the earlier statins; finally, there is a single commercially available drug in the third, high-potency generation of statins, rosuvastatin. Three unique chemical characteristics of rosuvastatin provide enhanced potency against HMG-CoA reductase.

The SUCRA rank results presented in our research are very close to previous findings \[[@B77]\], especially in terms of the efficacy rank of lowering LDL-C, TC, and TG and increasing HDL-C. Rosuvastatin and atorvastatin ranked No. 1 and No. 2 in lowering LDL-C, which is consistent with previous findings. In terms of the efficacy of increasing HDL-C, although the ranking was FLU\>LOV\>PRA\>PIT\>ATO\>SIM\>ROS\>PLA; not exactly like the results in previous studies, the SUCRA values of these statins were very close to our result (shown in [Figure 6](#fig6){ref-type="fig"}). The results of lowering the TG and TC efficacy rankings are generally consistent with previous studies. It is worth noting that as the first generation of statin, lovastatin ranked first in both TG and TC lowering rankings, which is not the same as we expected. We noticed that only one single study included the use of lovastatin in one group \[[@B73]\]. In this study, the adopted dose of lovastatin was 20-60 mg, relatively larger compared to a particular dose used on patients with simple dyslipidemia. Also, this lovastatin study had a rather long follow-up time of 2 years. These might be the reasons why lovastatin ranked first in both TG and TC lowering rankings.

As we can see from the results, rosuvastatin and atorvastatin have a high efficacy of lowering LDL-C and have a relatively good performance in regulating other blood lipid levels. They are also effective and widely used in clinical applications for regulating serum lipids and treating cardiovascular diseases.

The results of our review should be interpreted with caution in view of the following limitations. First of all, the follow-up periods of the included studies were between 14 days and 5 years. This variation will have an effect in reporting outcome measures using lipid mean change differences. Second, the doses of statins used in the eligible studies were not unified. We included all the RCTs using therapeutic doses of stains, because 10 of the included studies did not have a fixed statin dosage and their data cannot be grouped according to a certain dosage. This disunity of the drug doses might lead to bias in the network meta-analyses. In addition, some of the mean change and SD of lipids data were estimated according to the medians and quartiles collected from original articles, which might bring bias and inaccuracy in the data. This might also be one of the causes responsible for the inconsistency between direct and indirect evidences in several comparisons (see [Table 4](#tab4){ref-type="table"}).

5. Conclusions {#sec5}
==============

Rosuvastatin ranked 1st in LDL-C- and ApoB-lowering efficacy and ApoA1-increasing efficacy. Lovastatin ranked 1st in TC- and TG-lowering efficacy, and fluvastatin ranked 1st in HDL-C-increasing efficacy. The results should be interpreted with caution due to some limitations in our review. However, they can still provide some references and evidence-based foundation for drug selection in clinical application.
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The Supplementary Material consists of 4 parts. Appendix S1: the complete literature search strategy of the network meta-analysis (NMA). Appendix S2: description of the unit conversion methods used in this study. Appendix S3: league tables of the NMAs conducted for 5 of the outcomes. Appendix S4: the PRISMA checklist of the NMA.
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![Summary of the article search and selection process (flow chart). RCTs: randomized controlled trials.](CDTP2020-3987065.001){#fig1}

![Risk of bias graph: review of authors\' judgements about each risk of bias item presented as percentages across all included studies.](CDTP2020-3987065.002){#fig2}

![Risk of bias summary: review of authors\' judgements about each risk of bias item for each included study.](CDTP2020-3987065.003){#fig3}

![Network plots of eligible comparisons for (a) LDL-C change value, (b) HDL-C change value, (c) TC change value, (d) TG change value, (e) ApoA1 change value, and (f) ApoB change value among placebo and different statin treatments. The size of the nodes is weighted according to the number of trials available for each treatment. The treatments for which direct comparisons were available are linked with a line. The thickness of the line corresponds to the inverse variance of the direct comparisons which is a proxy for the sample size.](CDTP2020-3987065.004){#fig4}

![Network funnel plots of (a) LDL-C change value, (b) HDL-C change value, (c) TC change value, (d) TG change value, (e) ApoA1 change value, and (f) ApoB change value among placebo and different statin treatments (A: placebo, B: simvastatin, C: fluvastatin, D: atorvastatin, E: rosuvastatin, F: lovastatin, G: pravastatin, and H: pitavastatin).](CDTP2020-3987065.005){#fig5}

![The cumulative rank diagram of the estimated probability among placebo and the 7 compared statins in (a) LDL-C network meta-analysis, (b) HDL-C network meta-analysis, (c) TC network meta-analysis, (d) TG network meta-analysis, (e) ApoA1 network meta-analysis, and (f) ApoB network meta-analysis.](CDTP2020-3987065.006){#fig6}

###### 

General characteristics of studies included in the network meta-analyses.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Group (treatment)           No. of subjects   Mean age              Disease status                                                                          Country                              Population        Follow-up duration                         Outcomes
  ----------------------------------- --------------------------- ----------------- --------------------- --------------------------------------------------------------------------------------- ------------------------------------ ----------------- ------------------------------------------ -----------------------------------
  Zhu et al. \[[@B36]\]               ATO (20 mg)\                86                65.78 ± 6.77          Ischemic stroke                                                                         China                                Chinese           6 months                                   LDL-C, TC, TG
                                      PLA                                                                                                                                                                                                                                                           

  Tunçez et al. \[[@B37]\]            ATO (80 mg)\                63                57.67 ± 9.35 (ATO)\   Acute myocardial infarction                                                             Turkey                               Turk              4 weeks                                    LDL-C, HDL-C, TC
                                      ROS (40 mg)                                   58.30 ± 11.98 (ROS)                                                                                                                                                                                             

  Thondapu et al. \[[@B38]\]          ATO (20 mg)\                43                54.2 (ATO)\           De novo coronary artery disease                                                         USA, Japan, and Korea                UNK               1 year                                     LDL-C, HDL-C, TC, TG
                                      ROS (10 mg)                                   57.5 (ROS)                                                                                                                                                                                                      

  Mostafa et al. \[[@B17]\]           ATO (80 mg)\                100               54.6 ± 9 (ATO)\       Acute coronary syndrome/dyslipidemia                                                    Arab Republic of Egypt               Egyptians         1 month                                    LDL-C, HDL-C, TC, TG
                                      ROS (40 mg)                                   54.9 ± 8.4 (ROS)                                                                                                                                                                                                

  Zhao and Peng 2017 \[[@B24]\]       ATO (10 mg)\                414               59.5 ± 9.51           Hypercholesterolemia                                                                    China                                Chinese           6 weeks                                    LDL-C, HDL-C, TC, TG, ApoB
                                      ROS (5 mg, 10 mg)                                                                                                                                                                                                                                             

  Canas et al. \[[@B39]\]             PLA\                        38                15 ± 0.3              Type 1 diabetes                                                                         USA                                  American          6 months                                   LDL-C, HDL-C, TC, TG
                                      ATO                                                                                                                                                                                                                                                           

  Aydin et al. \[[@B40]\]             ATO (80 mg)\                120               58 ± 11               ST elevation myocardial infarction                                                      Turkey                               Turk              40 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ROS (20 mg)                                                                                                                                                                                                                                                   

  Moezzi et al. \[[@B18]\]            PLA\                        77                20-88                 Dyslipidemia                                                                            Iran                                 Iranian           1 month                                    LDL-C, HDL-C, TC
                                      SIM (40 mg)                                                                                                                                                                                                                                                   

  Correa et al. \[[@B41]\]            SIM (40 mg)\                79                18-70                 Hypertension                                                                            Brazil                               Brazilian         6 months                                   LDL-C
                                      PLA                                                                                                                                                                                                                                                           

  Koh et al. \[[@B42]\]               PLA\                        158               UNK                   Hypercholesterolemia                                                                    Korea                                Korean            2 months                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ROS (10 mg)\                                                                                                                                                                                                                                                  
                                      PRA (40 mg)                                                                                                                                                                                                                                                   

  Nozue et al. \[[@B43]\]             PIT (4 mg)\                 164               66 ± 9 67 ± 10        Coronary artery disease                                                                 Japan                                Japanese          8 months                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      PRA (20 mg)                                                                                                                                                                                                                                                   

  Nohara et al. \[[@B44]\]            ROS (5 mg)\                 298               Adult                 Carotid intima-media thickness                                                          Japan                                Japanese          24 months                                  LDL-C, HDL-C, TG
                                      PRA (10 mg)                                                                                                                                                                                                                                                   

  Lee et al. \[[@B45]\]               ATO (20 mg)\                271               ≧18 years old         Mild coronary atherosclerotic plaques                                                   Korea                                Korean            6 months                                   LDL-C, HDL-C, TC, TG
                                      ROS (10 mg)                                                                                                                                                                                                                                                   

  Nicholls et al. \[[@B46]\]          ATO (80 mg)\                1578              18-75                 Coronary disease                                                                        USA                                  American          UNK (endpoint time was during treatment)   LDL-C, HDL-C, TC, ApoB, ApoA1
                                      ROS (40 mg)                                                                                                                                                                                                                                                   

  Saku et al. \[[@B47]\]              ATO (10 mg)\                228               25-75                 Hypercholesterolemia                                                                    Japan                                Japanese          16 weeks                                   LDL-C, HDL-C, TG
                                      ROS (2.5 mg)\                                                                                                                                                                                                                                                 
                                      PIT (2 mg)                                                                                                                                                                                                                                                    

  Hernández et al. \[[@B19]\]         PLA\                        62                45-75                 Hypercholesterolemia                                                                    Spain                                Spanish           3 months                                   LDL-C, HDL-C, TC, TG
                                      ATO (10/40 mg)                                                                                                                                                                                                                                                

  Tsutamoto et al. \[[@B48]\]         ROS (2.5 mg)\               63                60.6 ± 10.9\          Cardiac sympathetic nerve activity in nondiabetic patient with dilated cardiomyopathy   Japan                                Japanese          6 months                                   LDL-C, HDL-C, TC, TG
                                      ATO (5 mg)                                    59.8 ± 8.8                                                                                                                                                                                                      

  Shimabukuro et al. \[[@B49]\]       PIT (2 mg)\                 31                30--79                Type 2 diabetes mellitus                                                                Japan                                Japanese          6 months                                   LDL-C, HDL-C, TC, TG
                                      ATO (10 mg)                                                                                                                                                                                                                                                   

  Bulbulia et al. \[[@B50]\]          PLA\                        20536             40-80                 High risk of vascular                                                                   Britain                              British           3-5 years                                  LDL-C, TC
                                      SIM (40 mg)                                                                                                                                                                                                                                                   

  Sansanayudh et al. \[[@B51]\]       PIT (1 mg)\                 100               ≧18                   Hypercholesterolemia                                                                    Thailand                             Thai              8 weeks                                    LDL-C, HDL-C, TC, TG
                                      ATO (10 mg)                                                                                                                                                                                                                                                   

  Bellia et al. \[[@B52]\]            SIM (20 mg)\                29                55 ± 3                Type 2 diabetes                                                                         Italy                                Italian           4 weeks                                    LDL-C, HDL-C, TC, TG
                                      ROS (20 mg)                                                                                                                                                                                                                                                   

  Su et al. \[[@B53]\]                SIM (40 mg)\                151               51--72                Type 2 diabetes mellitus                                                                China                                Chinese           12weeks                                    LDL-C, HDL-C, TC, TG
                                      ATO (10 mg)                                                                                                                                                                                                                                                   

  Ose et al. \[[@B25]\]               PIT (2 mg, 4 mg)\           857               18--75                Hypercholesterolemia or dyslipidemia                                                    Russia, Norway, UK, Finland, Italy   Multiple groups   12 months                                  LDL-C
                                      SIM (20 mg, 40 mg)                                                                                                                                                                                                                                            

  Kurabayashi et al. \[[@B54]\]       ATO (10 mg)\                405               ≧20                   Hypercholesterolemia                                                                    Japan                                Japanese          8 weeks                                    LDL-C, HDL-C, TC, TG
                                      ROS (5 mg)                                                                                                                                                                                                                                                    

  Young et al. \[[@B55]\]             ATO (40 mg)\                30                60 ± 8\               Coronary stenosis                                                                       Korea                                Korean            1 year                                     LDL-C, HDL-C, TC, TG
                                      ROS (20 mg)                                   62 ± 9                                                                                                                                                                                                          

  Kyeong et al. \[[@B56]\]            ATO (20 mg)\                117               63.5 ± 11.67\         Acute coronary syndrome                                                                 Korea                                Korean            40 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ROS (10 mg)                                   63.4 ± 10.88                                                                                                                                                                                                    

  Kom et al. \[[@B57]\]               PLA\                        24                35-60                 Hypercholesterolemia                                                                    Germany                              German            6 weeks                                    LDL-C, HDL-C, TC
                                      ATO (40 mg)                                                                                                                                                                                                                                                   

  Marketou et al. \[[@B58]\]          SIM (40 mg)\                88                35-70                 Hyperlipidemia                                                                          Greece                               Greek             3 weeks                                    LDL-C, HDL-C, TG
                                      ATO (40 mg)                                                                                                                                                                                                                                                   

  Pedersen et al. \[[@B59]\]          SIM (20 mg)\                8888              ≦80                   Myocardial infarction                                                                   Europe                               European          5 years                                    LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ATO (80 mg)                                                                                                                                                                                                                                                   

  Sirtori et al. \[[@B60]\]           ATO (10 mg)\                86                UNK                   Hyperlipidemia                                                                          Italy                                Italian           12 weeks                                   LDL-C
                                      PRA (20 mg)                                                                                                                                                                                                                                                   

  Nissen et al. \[[@B61]\]            PRA (40 mg)\                654               30-75                 Coronary atherosclerosis                                                                USA                                  American          18 months                                  LDL-C, HDL-C, TC, TG
                                      ATO (80 mg)                                                                                                                                                                                                                                                   

  Durazzo et al. \[[@B20]\]           PLA\                        100               UNK                   After vascular surgery                                                                  Brazil                               Brazilian         45 days                                    LDL-C, HDL-C, TC, TG
                                      ATO (20 mg)                                                                                                                                                                                                                                                   

  Bevilacqua et al. \[[@B62]\]        FLU (80 mg)\                100               45 to 71              Type 2 diabetes mellitus                                                                Italy                                Italian           3 months                                   LDL-C, HDL-C, TG, ApoB, ApoA1
                                      ATO (20 mg)                                                                                                                                                                                                                                                   

  Schwartz et al. \[[@B26]\]          ROS (5 mg, 10 mg)\          382               ≧18                   Hypercholesterolemia coronary heart disease                                             US\                                  American\         12 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ATO (10 mg)                                                                                                                                                 Canada                               Canadian                                                     

  Colhoun et al. \[[@B63]\]           PLA\                        2819              40--75                Type 2 diabetes mellitus                                                                UK\                                  European\         4 years                                    LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      ATO (10 mg)                                                                                                                                                 Ireland                              Irish                                                        

  Wissen et al. \[[@B64]\]            SIM (40 mg)\                325               UNK                   Heterozygous familial hypercholesterolemia                                              Netherland                           Dutch             2 years                                    LDL-C, HDL-C, TC, TG
                                      ATO (80 mg)                                                                                                                                                                                                                                                   

  Isaacsohn et al. \[[@B27]\]         PLA\                        195               18-70                 Hypertriglyceridemia                                                                    USA                                  American          6 weeks                                    LDL-C, HDL-C, TC
                                      SIM (20 mg/40 mg/80 mg)                                                                                                                                                                                                                                       

  McCrindle et al. \[[@B65]\]         ATO (10 mg-20 mg)\          187               10-17                 Hypercholesterolemia                                                                    USA\                                 American\         26 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      PLA                                                                                                                                                         Canada\                              Canadian\                                                    
                                                                                                                                                                                                  Europe\                              European\                                                    
                                                                                                                                                                                                  South Africa                         African                                                      

  Kadikoylu et al. \[[@B66]\]         ATO (10-20 mg)\             61                39--74                Primary hypercholesterolemia                                                            USA\                                 American\         24 weeks                                   LDL-C, HDL-C, TC, TG
                                      SIM (10-20 mg)                                                                                                                                              Europe                               European                                                     

  Manuel-Y-Keenoy et al. \[[@B67]\]   ATO (40 mg)\                24                UNK                   Type 1 diabetes                                                                         Belgium                              European          12 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      PLA                                                                                                                                                                                                                                                           

  Sever et al. \[[@B68]\]             PLA\                        10306             40--79                Hypertension                                                                            London                               British           5 years                                    LDL-C, HDL-C, TC, TG
                                      ATO (10 mg)                                                                                                                                                                                                                                                   

  Winkler et al. \[[@B69]\]           PLA\                        89                39--86                Type 2 diabetes mellitus                                                                Germany                              German            8 weeks                                    LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      FLU (80 mg)                                                                                                                                                                                                                                                   

  Tan et al. \[[@B21]\]               PLA\                        80                UNK                   Type 2 diabetes mellitus                                                                Hong Kong                            Chinese           6 months                                   LDL-C, HDL-C, TC
                                      ATO (10 mg-20 mg)                                                                                                                                                                                                                                             

  Wang and Ting \[[@B70]\]            ATO (10 mg)\                54                60                    Elevated LDL cholesterol                                                                Taiwan                               Chinese           8 weeks                                    LDL-C, HDL-C, TC, TG
                                      PLA                                                                                                                                                                                                                                                           

  Schrott et al. \[[@B71]\]           PLA\                        22                47-72                 Modestly overweight (potential tendency of dyslipidemia)                                USA                                  American          14 days                                    LDL-C, HDL-C, TC, TG
                                      ATO                                                                                                                                                                                                                                                           

  Serruys et al. \[[@B72]\]           PLA\                        1054              60 ± 9\               After successful coronary balloon angioplasty                                           Netherlands                          Dutch             26 weeks                                   LDL-C
                                      FLU \[80 mg (40 mg bid)\]                     61 ± 9                                                                                                                                                                                                          

  Mitropoulos et al. \[[@B28]\]       PLA\                        162               40-75                 Coronary heart disease                                                                  London                               British           2 years                                    LDL-C, HDL-C, TC, TG
                                      SIM (20 mg, 40 mg)                                                                                                                                                                                                                                            

  Lam et al. \[[@B73]\]               PLA\                        34                UNK                   Hypercholesterolemia                                                                    China                                Chinese           1 year                                     LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      LOV (20 mg\~60 mg)                                                                                                                                                                                                                                            

  Contermans et al. \[[@B74]\]        SIM\                        24                51 ± 8                Hypercholesterolemia                                                                    Holland                              Dutch             18 weeks                                   LDL-C, HDL-C, TC, TG
                                      PRA                                                                                                                                                                                                                                                           

  Mcdowell et al. \[[@B75]\]          PLA\                        27                UNK                   Primary hypercholesterolemia                                                            Ireland                              Irish             12 weeks                                   LDL-C, HDL-C, TC, TG, ApoB, ApoA1
                                      SIM (10 mg-40 mg)                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PLA: placebo; SIM: simvastatin; FLU: fluvastatin; ATO: atorvastatin; ROS: rosuvastatin; LOV: lovastatin; PRA: pravastatin; PIT: pitavastatin; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; ApoA1: Human Apolipoprotein A-1; ApoB: Human Apolipoprotein B; UNK: unknown.

###### 

Baseline characteristics of the biochemical values in the included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               LDL-C (mg·dl^−1^)                         HDL-C (mg·dl^−1^)        TC (mg·dl^−1^)           TG (mg·dl^−1^)           ApoA1                   ApoB
  ----------------------------------- ----------------------------------------- ------------------------ ------------------------ ------------------------ ----------------------- -----------------------
  Zhu et al. \[[@B36]\]               160.00 ± 11.97 (ATO)\                     NA                       222.48 ± 47.67 (ATO)\    266.39 ± 54.87 (ATO)\    NA                      NA
                                      157.91 ± 23.55 (PLA)                                               216.28 ± 60.08 (PLA)     270.81 ± 64.61 (PLA)                             

  Tunçez et al. \[[@B37]\]            120.08 ± 27.67 (ATO)\                     36.33 ± 9.76 (ATO)\      181.64 ± 35.42\          NA                       NA                      NA
                                      131.69 ± 24.61 (ROS)                      37.60 ± 10.72 (ROS)      (ATO)\                                                                    
                                                                                                         206.33 ± 36.00 (ROS)                                                      

  Thondapu et al. \[[@B38]\]          115 ± 28 (ATO)\                           50 ± 12 (ATO)\           203 ± 40 (ATO)\          183 ± 83 (ATO)\          NA                      NA
                                      100 ± 21 (ROS)                            51 ± 15 (ROS)            190 ± 44 (ROS)           245 ± 214 (ROS)                                  

  Mostafa et al. \[[@B17]\]           128 ± 45.3 (ATO)\                         36.4 ± 9.5 (ATO)\        191.7 ± 48.1 (ATO)\      188 (ATO)^\#^\           NA                      NA
                                      139.1 ± 37.6 (ROS)                        38.7 ± 13.3 (ROS)        199.2 ± 53.2 (ROS)       153 (ROS)^\#^                                    

  Zhao and Peng \[[@B24]\]            161.97                                    48.64                    245.69                   177.11                   1.45 mmol·l^−1^         1.20 mmol·l^−1^

  Canas et al. \[[@B39]\]             126 ± 5 (PLA)\                            63 ± 4 (PLA)\            206 ± 6 (PLA)\           88 ± 13 (PLA)\           4.01 ± 0.13 (PLA)\      2.4 ± 0.08 (PLA)\
                                      128 ± 4 (ATO)                             58 ± 3 (ATO)             203 ± 5 (ATO)            84 ± 7 (ATO)             3.83 ± 0.16 (ATO)\      2.43 ± 0.10 (ATO)\
                                                                                                                                                           mmol·l^−1^              mmol·l^−1^

  Aydin et al. \[[@B40]\]             144 ± 25 (ATO)\                           38 ± 8 (ATO)\            204 ± 31 (ATO)\          116 ± 72 (ATO)\          118 ± 23 (ATO)\         98 ± 19 (ATO)\
                                      141 ± 28 (ROS)                            38 ± 9 (ROS)             201 ± 35 (ROS)           109 ± 67 (ROS)           118 ± 26 (ROS)\         99 ± 22 (ROS)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Moezzi et al. \[[@B18]\]            118.38 ± 30.48 (PLA)\                     42.40 ± 11.92 (PLA)\     193.32 ± 39.65 (PLA)\    1.24 (PLA)^\#^\          NA                      NA
                                      131.44 ± 28.46 (SIM)                      44.08 ± 10.80 (SIM)      203.02 ± 36.11 (SIM)     1.325 (SIM)^\#^                                  

  Correa et al. \[[@B41]\]            133.3 ± 30.3 (PLA)\                       52.6 ± 12.1 (PLA)\       213.4 ± 36.9 (PLA)\      137.1 ± 61.8 (PLA)\      NA                      NA
                                      120.8 ± 31.0 (SIM)                        50.7 ± 11.8 (SIM)        198.9 ± 38.8 (SIM)       139.7 ± 65.3 (SIM)                               

  Koh et al. \[[@B42]\]               166 ± 4 (PLA)\                            54 ± 1 (PLA)\            248 ± 4 (PLA)\           138 ± 10 (PLA)\          153 ± 2 (PLA)\          126 ± 3 (PLA)\
                                      166 ± 4 (ROS)\                            53 ± 2 (ROS)\            246 ± 3 (ROS)\           136 ± 8 (ROS)\           152 ± 3 (ROS)\          127 ± 3 (ROS)\
                                      165 ± 3 (PRA)                             51 ± 1 (PRA)             241 ± 4 (PRA)            136 ± 8 (PRA)            151 ± 3 (PRA)\          128 ± 3 (PRA)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Nozue et al. \[[@B43]\]             123 ± 24 (PIT)\                           47 ± 12 (PIT)\           196 ± 31 (PIT)\          128 ± 75 (PIT)\          118 ± 21 (PIT)\         99 ± 19 (PIT)\
                                      135 ± 35 (PRA)                            46 ± 11 (PRA)            207 ± 37 (PRA)           129 ± 56 (PRA)           118 ± 20 (PRA)\         107 ± 27 (PRA)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Nohara et al. \[[@B44]\]            163.8 ± 30.9 (ROS)\                       54.2 ± 12.1 (ROS)\       NA                       149.6 ± 80.3 (ROS)\      NA                      NA
                                      165.1 ± 29.1 (PRA)                        54.8 ± 13.2 (PRA)                                 136.1 ± 69.8 (PRA)                               

  Lee et al. \[[@B45]\]               110 ± 31 (ATO)\                           40 ± 13 (ATO)\           183 ± 36 (ATO)\          165 ± 93 (ATO)\          NA                      NA
                                      109 ± 31 (ROS)                            40 ± 9 (ROS)             186 ± 34 (ROS)           182 ± 121 (ROS)                                  

  Nicholls et al. \[[@B46]\]          119.9 ± 28.9 (ATO)\                       44.7 ± 10.7 (ATO)\       193.5 ± 34.2 (ATO)\      130 (ATO)^\#^\           126.2 ± 23.3 (ATO)\     104.9 ± 21.7 (ATO)\
                                      120.0 ± 27.3 (ROS)                        45.3 ± 11.8 (ROS)        193.9 ± 34.1 (ROS)       128 (ROS)^\#^            128.0 ± 25.2 (ROS)\     105.4 ± 21.2 (ROS)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Saku et al. \[[@B47]\]              162 ± 24 (ATO)\                           56.7 ± 13.6 (ATO)\       NA                       142 ± 70 (ATO)\          NA                      NA
                                      172 ± 28 (ROS)\                           57.1 ± 13.4 (ROS)\                                142 ± 77 (ROS)\                                  
                                      164 ± 23 (PIT)                            59.0 ± 14.4 (PIT)                                 132 ± 71 (PIT)                                   

  Hernández et al. \[[@B19]\]         168 ± 28 (PLA)\                           55 ± 9 (PLA)\            255 ± 33 (PLA)\          125 (PLA)^\#^\           NA                      NA
                                      165 ± 33 (ATO)                            56 ± 11 (ATO)            252 ± 36 (ATO)           128 (ATO)^\#^                                    

  Tsutamoto et al. \[[@B48]\]         111 ± 28 (ROS)\                           43 ± 10 (ROS)\           NA                       192 ± 80 (ROS)\          NA                      NA
                                      115 ± 32 (ATO)                            42.6 ± 11 (ATO)                                   190 ± 108 (ATO)                                  

  Shimabukuro et al. \[[@B49]\]       166.80 ± 19.69 (PIT)\                     51.94 ± 10.85 (PIT)\     251.94 ± 22.09 (PIT)\    (PIT)\                   1.35 ± 0.17 (PIT)\      1.22 ± 0.10 (PIT)\
                                      163.32 ± 30.89 (ATO)                      55.04 ± 10.85 (ATO)      255.04 ± 30.62 (ATO)     (ATO)                    1.43 ± 0.10 (ATO)\      1.37 ± 0.18 (ATO)\
                                                                                                                                                           g·l^−1^                 g·l^−1^

  Bulbulia et al. \[[@B50]\]          131.27 ± 0.39 (PLA)\                      NA                       228.68 ± 0.39 (PLA)\     NA                       NA                      NA
                                      131.27 ± 0.39 (SIM)                                                228.68 ± 0.39 (SIM)                                                       

  Sansanayudh et al. \[[@B51]\]       175.99 ± 34.54 (PIT)\                     53.40 ± 15.59 (PIT)\     258.44 ± 41.25 (PIT)\    145.22 ± 56.95 (PIT)\    NA                      NA
                                      172.86 ± 34.53 (ATO)                      53.92 ± 13.05 (ATO)      255.16 ± 40.29 (ATO)     141.86 ± 49.08 (ATO)                             

  Bellia et al. \[[@B52]\]            139.77 ± 22.01 (SIM)\                     43.02 ± 7.75 (SIM)\      205.43 ± 26.74 (SIM)\    124.79 (SIM)\            NA                      NA
                                      133.59 ± 11.97 (ROS)                      34.11 ± 5.81 (ROS)       194.19 ± 17.83 (ROS)     128.33 (ROS)                                     

  Su et al. \[[@B53]\]                128.68 ± 33.33 (SIM)\                     43.80 ± 8.91 (SIM)\      179.07 ± 18.99 (SIM)\    151.34 ± 14.16 (SIM)\    NA                      NA
                                      127.13 ± 24.81 (ATO)                      44.57 ± 8.14 (ATO)       213.57 ± 24.03 (ATO)     152.22 ± 15.93 (ATO)                             

  Ose et al. \[[@B25]\]               183.85 (PIT)\                             52.06 (PIT)\             267.80 (PIT)\            160.03 (PIT)\            162.56 (PIT)\           160.74 (PIT)\
                                      184.05 (SIM)                              51.66 (SIM)              267.69 (SIM)             160.21 (SIM)             162.56 (SIM)\           162.64 (SIM)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Kurabayashi et al. \[[@B54]\]       109.3 ± 30.6 (ATO)\                       60.1 ± 15.3 (ATO)\       192.3 ± 34.8 (ATO)\      130.9 ± 72.2 (ATO)\      NA                      NA
                                      102.9 ± 25.1 (ROS)                        60.9 ± 17.6 (ROS)        186.1 ± 28.8 (ROS)       128.5 ± 67.4 (ROS)                               

  Young et al. \[[@B55]\]             121 ± 45 (ROS)\                           52 ± 7 (ROS)\            180 ± 52 (ROS)\          95 ± 43 (ROS)\           NA                      NA
                                      127 ± 37 (ATO)                            46 ± 12 (ATO)            182 ± 45 (ATO)           84 ± 54 (ATO)                                    

  Kyeong et al. \[[@B56]\]            139.1 ± 37.64 (ROS)\                      50.1 ± 13.76 (ROS)\      198.3 ± 43.24 (ROS)\     138.3 ± 70.68 (ROS)\     142.5 ± 28.92 (ROS)\    102.9 ± 30.49 (ROS)\
                                      137.7 ± 40.92 (ATO)                       48.8 ± 13.39 (ATO)       202.4 ± 45.48 (ATO)      140.2 ± 83.99 (ATO)      137.9 ± 27.25 (ATO)\    108.8 ± 29.73 (ATO)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Kom et al. \[[@B57]\]               202 ± 21 (PLA)\                           50.6 ± 13.1 (PLA)\       284 ± 30 (PLA)\          NA                       NA                      NA
                                      231 ± 54 (ATO)                            59.1 ± 11.6 (ATO)        320 ± 61 (ATO)                                                            

  Marketou et al. \[[@B58]\]          178 ± 210 (ATO)\                          40 ± 90 (ATO)\           279 ± 240 (ATO)\         227 ± 117 (ATO)\         NA                      NA
                                      177 ± 210 (SIM)                           42 ± 11 (SIM)            278 ± 310 (SIM)          242 ± 880 (SIM)                                  

  Pedersen et al. \[[@B59]\]          121.4 ± 0.5 (SIM)\                        46.1 ± 0.2 (SIM)\        195.9 ± 0.6 (SIM)\       146.6 ± 1.1 (SIM)\       1.39 ± 0.01 (SIM)\      1.19 ± 0.01 (SIM)\
                                      121.6 ± 0.5 (ATO)                         46.0 ± 0.2 (ATO)         196.8 ± 0.6 (ATO)        151.1 ± 1.2 (ATO)        1.39 ± 0.01 (ATO)\      1.19 ± 0.01 (ATO)\
                                                                                                                                                           g·l^−1^                 g·l^−1^

  Sirtori et al. \[[@B60]\]           210.9 ± 46.6 (ATO)\                       45.6 ± 13.2 (ATO)\       305.9 ± 54.1 (ATO)\      289.1 ± 210.8 (ATO)\     166.4 ± 28.4 (ATO)\     153.2 ± 33.5 (ATO)\
                                      225.0 ± 43.9 (PRA)                        47.6 ± 12.0 (PRA)        312.6 ± 43.8 (PRA)       237.3 ± 138.2 (PRA)      167.1 ± 30.6 (PRA)\     161.5 ± 29.8 (PRA)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Nissen et al. \[[@B61]\]            150.2 ± 25.9 (PRA)\                       42.9 ± 11.4 (PRA)\       232.6 ± 34.1 (PRA)\      197.7 ± 105.6 (PRA)\     NA                      153.0 ± 22.5 (PRA)\
                                      150.2 ± 27.9 (ATO)                        42.3 ± 9.9 (ATO)         231.8 ± 34.2 (ATO)       197.2 ± 95.7 (ATO)                               152.4 ± 24.3 (ATO)\
                                                                                                                                                                                   mg·dl^−1^

  Durazzo et al. \[[@B20]\]           144.60 ± 32.58 (ATO)\                     44.41 ± 9.37 (ATO)\      222.74 ± 51.59 (ATO)\    128 (ATO)^\#^\           NA                      NA
                                      139.65 ± 41.62 (PLA)                      43.38 ± 13.42 (PLA)      214.52 ± 53.25 (PLA)     156.18 (PLA)^\#^                                 

  Bevilacqua et al. \[[@B62]\]        149 ± 33 (FLU)\                           41 ± 7 (FLU)\            NA                       437 ± 287 (FLU)\         NA                      NA
                                      141 ± 25 (ATO)                            41 ± 7 (ATO)                                      411 ± 271 (ATO)                                  

  Schwartz et al. \[[@B26]\]          188 ± 19 (ROS 5 mg)\                      46 ± 10 (ROS 5 mg)\      274 ± 26 (ROS 5 mg)\     196 ± 71 (ROS 5 mg)\     143 ± 23 (ROS 5 mg)\    182 ± 21 (ROS 5 mg)\
                                      186 ± 20 (ROS 10 mg)\                     47 ± 10 (ROS 10 mg)\     272 ± 24 (ROS 10 mg)\    195 ± 72 (ROS 10 mg)\    143 ± 25 (ROS 10 mg)\   176 ± 20 (ROS 10 mg)\
                                      188 ± 23 (ATO)                            47 ± 11 (ATO)            275 ± 27 (ATO)           202 ± 77 (ATO)           142 ± 23 (ATO)\         183 ± 22 (ATO)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Colhoun et al. \[[@B63]\]           116.6 ± 27.03 (PLA)\                      55.04 ± 13.18 (PLA)\     207.4 ± 31.78 (PLA)\     147.80 (PLA)\#\          1530 ± 294 (PLA)\       1150 ± 241 (PLA)\
                                      117.4 ± 27.80 (ATO)                       53.88 ± 12.40 (ATO)      207.8 ± 32.17 (ATO)      150.45 (ATO)\#           1530 ± 271 (ATO)\       1170 ± 243 (ATO)\
                                                                                                                                                           mg·l^−1^                mg·l^−1^

  Wissen et al. \[[@B64]\]            321.6 ± 78.38 (SIM) 185.7 ± 53.28 (ATO)   44.96 ± 10.85 (SIM)\     398.1 ± 81.40 (SIM)\     163.7 ± 118.6 (SIM)\     NA                      NA
                                                                                45.74 ± 12.40 (ATO)      387.2 ± 72.48 (ATO)      165.5 ± 96.47 (ATO)                              

  Isaacsohn et al. \[[@B27]\]         NA                                        NA                       NA                       405 \#                   NA                      NA

  McCrindle et al. \[[@B65]\]         218.5 ± 3.47 (ATO)\                       46.12 ± 0.78 (ATO)\      286.1 ± 3.88 (ATO)\      102.7 ± 5.31 (ATO)\      1.25 ± 0.02 (ATO)\      1.86 ± 0.03 (ATO)\
                                      230.1 ± 6.95 (PLA)                        46.51 ± 1.55 (PLA)       298.8 ± 7.36 (PLA)       106.2 ± 7.97 (PLA)       1.25 ± 0.03 (PLA)\      1.94 ± 0.05 (PLA)\
                                                                                                                                                           g·l^−1^                 g·l^−1^

  Kadikoylu et al. \[[@B66]\]         168.5 ± 29.8 (ATO)\                       53.6 ± 9.5 (ATO)\        263.8 ± 29.9 (ATO)\      221.5 ± 92.9 (ATO)\      NA                      NA
                                      172.1 ± 22.5 (SIM)                        57.5 ± 19.0 (SIM)        264.6 ± 23.7 (SIM)       191.2 ± 92.3 (SIM)                               

  Manuel-Y-Keenoy et al. \[[@B67]\]   185.7 ± 61.78 (ATO)\                      53.10 ± 11.24 (ATO)\     263.6 ± 64.34 (ATO)\     117.7 ± 27.44 (ATO)\     122 ± 25 (ATO)\         142 ± 37 (ATO)\
                                      139.0 ± 35.91 (PLA)                       51.16 ± 13.18 (PLA)      215.5 ± 39.15 (PLA)      125.7 ± 40.71 (PLA)      116 ± 24 (PLA)\         116 ± 24 (PLA)\
                                                                                                                                                           mg·dl^−1^               mg·dl^−1^

  Sever et al. \[[@B68]\]             131.3 ± 27.03 (ATO)\                      50.39 ± 15.50 (ATO)\     213.2 ± 31.01 (ATO)\     150.5 ± 79.65 (ATO)\     NA                      NA
                                      131.3 ± 27.03 (PLA)                       50.39 ± 15.50 (PLA)      213.2 ± 31.01 (PLA)      150.5 ± 79.65 (PLA)                              

  Winkler et al. \[[@B69]\]           130.1 ± 28.19 (FLU)\                      45.35 ± 12.02 (FLU)\     245.0 ± 37.98 (FLU)\     213.3 ± 121.3 (FLU)\     NA                      1.35 ± 0.24 (FLU)\
                                      238.2 ± 37.84 (PLA)                       42.25 ± 13.95 (PLA)      239.2 ± 37.98 (PLA)      215.1 ± 99.12 (PLA)                              1.36 ± 0.23 (PLA)\
                                                                                                                                                                                   g·l^−1^

  Tan et al. \[[@B21]\]               165.6 ± 20.08 (PLA)\                      43.41 ± 8.91 (PLA)\      237.2 ± 24.81 (PLA)\     124.8 (PLA) \#\          NA                      NA
                                      171.8 ± 33.59 (ATO)                       46.12 ± 8.91 (ATO)       246.1 ± 37.98 (ATO)      122.1 (ATO) \#                                   

  Wang and Ting \[[@B70]\]            192.70 ± 20.00 (ATO)\                     45.4 ± 92.1 (ATO)\       267.0 ± 24.9 (ATO)\      144.8 ± 45.3 (ATO)\      NA                      NA
                                      187.29 ± 18.31 (PLA)                      45.11 ± 10.6 (PLA)       260.1 ± 21.9 (PLA)       138.5 ± 50.1 (PLA)                               

  Schrott et al. \[[@B71]\]           NA                                        50 ± 3.5 (PLA)\          217 ± 6.3 (PLA)\         140 ± 15.5 (PLA)\        NA                      NA
                                                                                53 ± 4.8 (ATO)           226 ± 10.5 (ATO)         137 ± 20.1 (ATO)                                 

  Serruys et al. \[[@B72]\]           152.9 ± 32.82 (FLU)\                      41.09 ± 10.47 (FLU)\     222.9 ± 39.15 (FLU)\     149.6 ± 74.34 (FLU)\     NA                      NA
                                      152.5 ± 33.59 (PLA)                       41.86 ± 10.85 (PLA)      223.7 ± 39.92 (PLA)      141.6 ± 73.46 (PLA)                              

  Mitropoulos et al. \[[@B28]\]       182.6 ± 40.54 (SIM40)\                    44.57 ± 13.18 (SIM40)\   270.2 ± 43.41 (SIM40)\   214.2 ± 114.2 (SIM40)\   NA                      NA
                                      191.1 ± 42.08 (SIM20)\                    46.12 ± 15.12 (SIM20)\   277.1 ± 54.26 (SIM20)\   197.4 ± 113.3 (SIM20)\                           
                                      268.0 ± 40.93 (PLA)                       44.96 ± 10.47 (PLA)      269.0 ± 41.09 (PLA)      219.5 ± 132.8 (PLA)                              

  Lam et al. \[[@B73]\]               166.0 ± 11.58 (LOV)\                      42.64 ± 1.94 (LOV)\      255.8 ± 3.88 (LOV)\      194.7 ± 26.55 (LOV)\     2.01 ± 0.06 (LOV)\      1.55 ± 0.05 (LOV)\
                                      158.3 ± 7.72 (PLA)                        42.64 ± 2.71 (PLA)       244.2 ± 3.88 (PLA)       256.7 ± 44.25 (PLA)      2.02 ± 0.06 (PLA)\      1.36 ± 0.05 (PLA)\
                                                                                                                                                           g·l^−1^                 g·l^−1^

  Contermans et al. \[[@B74]\]        231.7 ± 32.82 (SIM)\                      42.64 ± 10.47 (SIM)\     303.9 ± 33.72 (SIM)\     147.0 ± 52.22 (SIM)\     NA                      NA
                                      234.0 ± 43.63 (PRA)                       44.57 ± 4.65 (PRA)       307.0 ± 41.86 (PRA)      132.8 ± 17.70 (PRA)                              

  Mcdowell et al. \[[@B75]\]          366.8 ± 23.17 (PLA)\                      56.59 ± 3.49 (PLA)\      453.5 ± 23.26 (PLA)\     177.0 ± 44.25 (PLA)\     1.45 ± 0.07 (PLA)\      1.69 ± 0.13 (PLA)\
                                      351.4 ± 23.17 (SIM)                       52.71 ± 4.26 (SIM)       411.9 ± 23.26 (SIM)      230.1 ± 44.25 (SIM)      1.41 ± 0.07 (SIM)\      1.55 ± 0.11 (SIM)\
                                                                                                                                                           g·l^−1^                 g·l^−1^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PLA: placebo; SIM: simvastatin; FLU: fluvastatin; ATO: atorvastatin; ROS: rosuvastatin; LOV: lovastatin; PRA: pravastatin; PIT: pitavastatin; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; ApoA1: Human Apolipoprotein A-1; ApoB: Human Apolipoprotein B. Most data are shown as the "mean ± SD (treatment group)." ^\#^Data are shown as the median. NA: not applicable.

###### 

Global inconsistency test results for the 6 different outcomes.

  Outcomes    LDL-C    HDL-C    TC       **TG**       ApoA1    ApoB
  ----------- -------- -------- -------- ------------ -------- --------
  *P* value   0.8320   0.9886   0.9950   **0.0052**   0.2333   0.8143

###### 

Inconsistency revealed in the node-splitting tests.

  Outcomes of the NMAs   Inconsistency was observed between direct and indirect evidences in these comparisons
  ---------------------- ---------------------------------------------------------------------------------------
  LDL-C                  Placebo vs. lovastatin
  HDL-C                  Placebo vs. lovastatin
  TC                     Placebo vs. fluvastatin; placebo vs. lovastatin
  TG                     Placebo vs. lovastatin
  ApoA1                  Placebo vs. fluvastatin; fluvastatin vs. atorvastatin
  ApoB                   None

###### 

SUCRA values of placebo and the 7 statin treatments in NMAs conducted separately for 6 outcomes.

  Treatments     LDL-C      HDL-C      TC          TG         ApoA1      ApoB
  -------------- ---------- ---------- ----------- ---------- ---------- ----------
  Placebo        0.4        18.3       0.4         2.3        33.7       13.8
  Simvastatin    48.4       44.5       50.0        34.0       75.2       66.2
  Fluvastatin    36.4       **74.5**   37.4        56.2       69.2       40.4
  Atorvastatin   76.7       47.9       72.4        48.6       56.4       64.5
  Rosuvastatin   **93.1**   29.9       69.5        63.1       **82.8**   **72.9**
  Lovastatin     27.8       63.3       **100.0**   **91.4**   40.3       21.7
  Pravastatin    47.6       62.1       24.5        67.8       18.8       56.6
  Pitavastatin   69.5       59.4       45.8        36.6       23.5       63.9

###### 

League table of the LDL-C network meta-analysis results among placebo and 7 statins. (Results with statistical significance are shown in bold.).

                 Rosuvastatin                  Atorvastatin                  Pitavastatin                  Simvastatin                   Pravastatin                   Fluvastatin                   Lovastatin              Placebo
  -------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------- --------------------------
  Rosuvastatin   Rosuvastatin                  5.87 (-5.72, 17.47)           8.26 (-12.46, 28.98)          15.35 (-0.24, 30.95)          16.15 (-2.87, 35.16)          23.03 (-4.12,50.19)           33.67 (-9.49, 76.83)    **72.28 (57.08, 87.48)**
  Atorvastatin   -5.87 (-17.47, 5.72)          Atorvastatin                  2.38 (-16.71, 21.48)          9.48 (-2.91, 21.88)           10.27 (-7.68, 28.22)          17.16 (-7.82,42.14)           27.79 (-14.15, 69.74)   **66.40 (55.10, 77.71)**
  Pitavastatin   -8.26 (-28.98, 12.46)         -2.38 (-21.48, 16.71)         Pitavastatin                  7.10 (-12.51, 26.71)          7.89 (-14.86, 30.63)          14.78 (-16.04,45.59)          25.41 (-20.05, 70.87)   **64.02 (43.17, 84.87)**
  Simvastatin    -15.35 (-30.95, 0.24)         -9.48 (-21.88, 2.91)          -7.10 (-26.71, 12.51)         Simvastatin                   0.79 (-18.99, 20.57)          7.68 (-18.77, 34.12)          18.31 (-24.09, 60.71)   **56.92 (44.05, 69.80)**
  Pravastatin    -16.15 (-35.16, 2.87)         -10.27 (-28.22, 7.68)         -7.89 (-30.63, 14.86)         -0.79 (-20.57, 18.99)         Pravastatin                   6.89 (-23.21, 36.99)          17.52 (-27.45, 62.49)   **56.13 (36.37, 75.89)**
  Fluvastatin    -23.03 (-50.19, 4.12)         -17.16 (-42.14, 7.82)         -14.78 (-45.59, 16.04)        -7.68 (-34.12, 18.77)         -6.89 (-36.99, 23.21)         Fluvastatin                   10.64 (-36.38, 57.66)   **49.25 (25.19, 73.31)**
  Lovastatin     -33.67 (-76.83, 9.49)         -27.79 (-69.74, 14.15)        -25.41 (-70.87, 20.05)        -18.31 (-60.71, 24.09)        -17.52 (-62.49, 27.45)        -10.64 (-57.66, 36.38)        Lovastatin              38.61 (-1.79, 79.01)
  Placebo        **-72.28 (-87.48, -57.08)**   **-66.40 (-77.71, -55.10)**   **-64.02 (-84.87, -43.17)**   **-56.92 (-69.80, -44.05)**   **-56.13 (-75.89, -36.37)**   **-49.25 (-73.31, -25.19)**   -38.61 (-79.01, 1.79)   Placebo

###### 

Global inconsistency test results (*P* values) in NMAs separately conducted for 6 outcomes.

            LDL-C        HDL-C    TC       TG           ApoA1    ApoB
  --------- ------------ -------- -------- ------------ -------- --------
  Group 1   **0.0000**   0.8766   0.6987   0.9497       NA^∗∗^   NA^∗∗^
  Group 2   0.9991       0.9526   0.8748   **0.0000**   NA^∗∗^   NA^∗∗^
  Group 3   0.3887       0.1622   NA^∗^    0.1788       NA^∗∗^   NA^∗∗^

NA^∗^: data contain no potential source of inconsistency; NA^∗∗^: too few articles included in the subgroup analysis, data contain no potential source of heterogeneity.

###### 

Inconsistency revealed in the subgroup NMA node-splitting tests.

  Outcomes of the NMAs   Groups                                   Inconsistency was observed between direct and indirect evidences in these comparisons
  ---------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------
  LDL-C                  Group 1                                  Placebo vs. fluvastatin; atorvastatin vs. rosuvastatin; atorvastatin vs. lovastatin; rosuvastatin vs. lovastatin
  Group 2                Placebo vs. rosuvastatin                 
  Group 3                None (no indirect comparison involved)   
                                                                  
  HDL-C                  Group 1                                  None (no indirect comparison involved)
  Group 2                Placebo vs. rosuvastatin                 
  Group 3                None (no indirect comparison involved)   
                                                                  
  TC                     Group 1                                  None (no indirect comparison involved)
  Group 2                None (no indirect comparison involved)   
  Group 3                None (no indirect comparison involved)   
                                                                  
  TG                     Group 1                                  None (no indirect comparison involved)
  Group 2                None (no indirect comparison involved)   
  Group 3                None (no indirect comparison involved)   
                                                                  
  ApoA1                  Group 1                                  NA^∗∗^
  Group 2                NA^∗∗^                                   
  Group 3                NA^∗∗^                                   
                                                                  
  ApoB                   Group 1                                  NA^∗∗^
  Group 2                NA^∗∗^                                   
  Group 3                NA^∗∗^                                   

NA^∗∗^: too few articles included in the subgroup analysis, data contain no potential source of heterogeneity.

###### 

Sensitivity analysis results for different follow-up durations. (Global inconsistency test results in NMAs for TG, separately conducted in the 4 follow-up duration groups.).

  Groups                       Group 1      Group 2   Group 3   Group 4
  ---------------------------- ------------ --------- --------- ---------
  Number of included studies   13           7         3         3
  *P* value                    **0.0227**   0.6174    NA^∗∗^    NA^∗∗^

NA^∗∗^: too few articles included in the subgroup analysis, data contain no potential source of heterogeneity.

[^1]: Academic Editor: John D. Imig
